Overview

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up.
Phase:
Phase 3
Details
Lead Sponsor:
Braeburn Pharmaceuticals
Treatments:
Buprenorphine